Both ARCHER 1028 and ARCHER 1009 trials showed that on target adverse events related to the inhibition of EGFR WT in normal tissues were significantly increased with dacomitinib compared to erlotinib, mainly skin rash, paronychia, and gastrointestinal toxicities (24, 26). Here, EGFR is linked to paronychia.